• aTyr Pharma published Journal of Biological Chemistry data showing anti-fibrotic activity for ATYR0101, a DARS-derived fusion protein.
• Mechanism targets LTBP-1 to trigger myofibroblast apoptosis, with activity dependent on active TGF-β.
• In a bleomycin lung fibrosis model, ATYR0101 reduced collagen content and Ashcroft score, outperforming nintedanib control.
• Program remains in IND-enabling studies, with plans to enter the clinic in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610130800PRIMZONEFULLFEED9844343) on October 13, 2026, and is solely responsible for the information contained therein.